Purchase this article with an account.
Rubens C. Siqueira, Andre Messias, Julio C. Voltarelli, Katharina V. Messias, Rafael S. Arcieri, Rodrigo Jorge; Fixation Stability and Central Retinal Sensitivity after Intravitreal Autologous Bone-Marrow Stem Cells for Hereditary Retinal Dystrophy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6432.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate fixation stability and macular sensitivity in patients with retinitis pigmentosa (RP), before and 30 days after single intravitreal injection of autologous bone marrow stem cells (ABMSC).
A prospective, phase II, nonrandomized trial, including 20 patients with RP. Fixation stability was assessed calculating the bivariate contour ellipse area (BCEA) for fixations recorded during microperimetric (36 test poins / 10 degrees visual field radios from fixation point; MAIA - CenterVue - Italy) test, and macular sensitivity was calculated as the average threshold (AVTH) for the tested points. Examinations were performed at baseline and 30 days after intravitreal ABMSC (0.1 ml; ~1000000 cells) into one study eye of each patient.
No adverse side effect due to the injection was observed for the 20 patients that finished the first month follow-up. Although on average slightly narrowed, no significant change was observed for BCEA after treatment. Mean ± SE BCEA was 4.2 ± 1.6 degrees at baseline and 2.9 ± 0.9 degrees (P=0.4800; Wilcoxon Signed Rank) 30 days after treatment. There was a small, but statistically significant increase on AVTH in this period. Mean ± SE AVTH was 11.2 ± 1.7 dB at baseline, with an intra-individual difference of 1.2 ± 0.5 dB (P=0.0359) 30 days after treatment. The contralateral eye showed no significant changes in this period.
Intravitreal injection of ABMSC in advanced RP was associated with slight improvement on macular sensitivity measured by microperimetry. Further analysis from this trial will investigate this findings at long-term, and if there are correlations between this findings and other retinal functional or morphological changes related to intravitreal ABMSC for RP.
Clinical Trial: :
This PDF is available to Subscribers Only